0000899243-23-002193.txt : 20230119
0000899243-23-002193.hdr.sgml : 20230119
20230119171618
ACCESSION NUMBER: 0000899243-23-002193
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230119
FILED AS OF DATE: 20230119
DATE AS OF CHANGE: 20230119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EVNIN ANTHONY B
CENTRAL INDEX KEY: 0001239241
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34655
FILM NUMBER: 23538199
MAIL ADDRESS:
STREET 1: C/O VENROCK ASSOCIATES
STREET 2: 7 BRYANT PARK, 23RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001325879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043581650
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30 WINTER STREET
CITY: BOSTON
STATE: MA
ZIP: 02108
BUSINESS PHONE: 857-400-0101
MAIL ADDRESS:
STREET 1: 30 WINTER STREET
CITY: BOSTON
STATE: MA
ZIP: 02108
FORMER COMPANY:
FORMER CONFORMED NAME: AVEO PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20050503
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-19
1
0001325879
AVEO PHARMACEUTICALS, INC.
AVEO
0001239241
EVNIN ANTHONY B
C/O AVEO PHARMACEUTICALS, INC.
30 WINTER STREET
BOSTON
MA
02108
1
0
0
0
Common Stock
2023-01-19
4
D
0
41841
15.00
D
0
D
Stock Option (Right to Buy)
25.90
2023-01-19
4
D
0
1250
D
2023-05-29
Common Stock
1250
0
D
Stock Option (Right to Buy)
15.70
2023-01-19
4
D
0
1250
D
2024-06-19
Common Stock
1250
0
D
Stock Option (Right to Buy)
16.10
2023-01-19
4
D
0
2515
D
2025-04-02
Common Stock
2515
0
D
Stock Option (Right to Buy)
20.00
2023-01-19
4
D
0
2000
D
2025-05-28
Common Stock
2000
0
D
Stock Option (Right to Buy)
9.20
2023-01-19
4
D
0
6402
D
2026-05-26
Common Stock
6402
0
D
Stock Option (Right to Buy)
7.00
2023-01-19
4
D
0
7785
D
2027-06-21
Common Stock
7785
0
D
Stock Option (Right to Buy)
22.70
2023-01-19
4
D
0
4000
D
2028-06-17
Common Stock
4000
0
D
Stock Option (Right to Buy)
7.60
2023-01-19
4
D
0
4000
D
2029-06-11
Common Stock
4000
0
D
Stock Option (Right to Buy)
7.52
2023-01-19
4
D
0
4000
D
2030-06-09
Common Stock
4000
0
D
Stock Option (Right to Buy)
7.27
2023-01-19
4
D
0
12500
D
2031-06-08
Common Stock
12500
0
D
Stock Option (Right to Buy)
4.27
2023-01-19
4
D
0
22500
D
2032-06-06
Common Stock
22500
0
D
Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.
This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration").
/s/ Danielle V. Holland, attorney in fact
2023-01-19